Ken Griffin
FATE icon

Ken Griffin’s Fate Therapeutics FATE Stock Holding History

Ken Griffin’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.13M Buy
942,926
+193,590
+26% +$236K ﹤0.01% 7389
2025
Q4 		$736K Sell
749,336
-75,209
-9% -$90.3K ﹤0.01% 8100
2025
Q3 		$1.04M Sell
824,545
-3,719,322
-82% -$4.01M ﹤0.01% 7461
2025
Q2 		$5.09M Buy
4,543,867
+254,708
+6% +$296K ﹤0.01% 4082
2025
Q1 		$3.39M Sell
4,289,159
-93,098
-2% -$114K ﹤0.01% 4549
2024
Q4 		$7.23M Buy
4,382,257
+100,180
+2% +$252K ﹤0.01% 3397
2024
Q3 		$15M Sell
4,282,077
-205,949
-5% -$801K ﹤0.01% 2378
2024
Q2 		$14.7M Buy
4,488,026
+1,356,500
+43% +$5.94M ﹤0.01% 2336
2024
Q1 		$23M Buy
3,131,526
+465,318
+17% +$2.88M ﹤0.01% 1930
2023
Q4 		$9.97M Buy
2,666,208
+646,576
+32% +$1.53M ﹤0.01% 2849
2023
Q3 		$4.28M Sell
2,019,632
-262,899
-12% -$871K ﹤0.01% 3912
2023
Q2 		$10.9M Buy
2,282,531
+623,759
+38% +$3.44M ﹤0.01% 2569
2023
Q1 		$9.46M Buy
1,658,772
+236,635
+17% +$1.43M ﹤0.01% 2885
2022
Q4 		$14.3M Buy
1,422,137
+1,028,798
+262% +$19.3M ﹤0.01% 2352
2022
Q3 		$8.81M Buy
393,339
+41,110
+12% +$1.19M ﹤0.01% 2954
2022
Q2 		$8.73M Sell
352,229
-67,693
-16% -$1.87M ﹤0.01% 2869
2022
Q1 		$16.3M Buy
419,922
+247,765
+144% +$9.59M ﹤0.01% 2246
2021
Q4 		$10.1M Sell
172,157
-6,775
-4% -$384K ﹤0.01% 3061
2021
Q3 		$10.6M Sell
178,932
-507,552
-74% -$39.8M ﹤0.01% 2979
2021
Q2 		$59.6M Sell
686,484
-155,665
-18% -$12.5M 0.01% 994
2021
Q1 		$69.4M Sell
842,149
-266,491
-24% -$25.5M 0.02% 789
2020
Q4 		$101M Sell
1,108,640
-1,482,930
-57% -$92.1M 0.03% 547
2020
Q3 		$104M Sell
2,591,570
-685,907
-21% -$23.9M 0.03% 450
2020
Q2 		$112M Buy
3,277,477
+1,008,949
+44% +$30.1M 0.04% 355
2020
Q1 		$50.4M Buy
2,268,528
+1,422,711
+168% +$36M 0.02% 636
2019
Q4 		$16.6M Buy
845,817
+271,692
+47% +$4.31M 0.01% 1666
2019
Q3 		$8.92M Buy
+574,125
New +$11M ﹤0.01% 2351
2019
Q2 		– Sell
-869,789
Closed -$15.7M – 9357
2019
Q1 		$15.3M Sell
869,789
-368,653
-30% -$5.82M 0.01% 1584
2018
Q4 		$15.9M Buy
1,238,442
+453,196
+58% +$6.32M 0.01% 1419
2018
Q3 		$12.8M Buy
785,246
+677,366
+628% +$8.01M 0.01% 1832
2018
Q2 		$1.22M Buy
+107,880
New +$1.19M ﹤0.01% 4869
2018
Q1 		– Sell
-10,370
Closed -$63K – 8413
2017
Q4 		$63K Buy
+10,370
New +$46.3K ﹤0.01% 7558
2017
Q2 		– Sell
-13,746
Closed -$63K – 7634
2017
Q1 		$63K Buy
+13,746
New +$50.3K ﹤0.01% 6991
2016
Q1 		– Sell
-14,464
Closed -$49K – 7110
2015
Q4 		$49K Buy
+14,464
New +$60.8K ﹤0.01% 7326

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ken Griffin's FATE Position: Q1 2026 in Review

Ken Griffin increased its Fate Therapeutics (FATE) stake by 26% in Q1 2026, buying an estimated $236K and bringing the position to 942,926 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #7389.

Ken Griffin first reported a position in FATE in Q4 2015 and has held it in 34 quarters since. The position peaked at $112M in Q2 2020. 158 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Ken Griffin held 942,926 shares of Fate Therapeutics worth $1.13M as of Q1 2026.
  • Ken Griffin bought 193,590 Fate Therapeutics shares in Q1 2026, an estimated $236K.
  • Fate Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #7389 holding.
  • Ken Griffin first reported a position in Fate Therapeutics in Q4 2015 and has held it in 34 quarters since.
  • Ken Griffin's Fate Therapeutics position peaked at $112M in Q2 2020.
  • 158 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.